An excellent example in pediatric neuro-oncology is the use of trametinib (MEK inhibitor) and dabrafenib (BRAF inhibitor) in patients with BRAF V600-mutant low-grade glioma, which exhibited a better overall response rate compared to standard chemotherapy regimen [113]. This evidence concerns the gene MAP2K7 and glioma.